Abstract
Danish pharmaceutical company, Lundbeck, made two key acquisitions that strengthen its position central nervous system drugs. It acquired LifeHealth Ltd for its stake in Xenazine® (terbenazine) a treatment for a symptom of Huntington’s disease and a Danish biotech, NeuronIcon to gain technologies for the treatment of brain damage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
